hackint0sh/New-Dataset huggingface dataset:
Intervention: The investigators propose a 3-arm RCT to compare rates of completing the next step in the HPV vaccination series at six months and completing the HPV vaccination series at 13 months between Auto, Auto-Plus, and UC arms. P/C of children/adolescents (C/A) who have not completed the series will be randomized 1:1:1 to study arms. Participants will be assessed for eligibility and enrolled, with a total participant time in the study of 13 months, for a total of 25 months of enrollment, participation, and follow-up. primaryPurpose: PREVENTION masking: DOUBLE maskingDescription: Clinic analysts will create a real-time list of patients due for an initial HPV vaccine dose. P/C of remaining C/A patients will be individually randomized to either Auto or Auto-Plus intervention or usual care (UC) in a 1:1:1 ratio. The PREVENT study will only target one child/adolescent per parent/caregiver (siblings will be excluded from intervention assessments). The investigators will use automated codes to manage interventions so that eligible patients get initial HPV vaccines on time and P/C are prompted to repeat vaccination, as recommended. The investigators will select a cohort of approximately 1,038 P/C patients from the 4 clinics, randomized to intervention arms (UC, Auto, and Auto-Plus). Intervention activities largely mimic clinic processes, and clinicians and participants will be unaware of which intervention study arm the P/C has been assigned. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 519 type: ESTIMATED name: PREVENT measure: Intervention Reach: Vaccination Next Step Initiation (Next HPV dose completion) measure: RCT Arm Effectiveness: Next HPV Vaccination Step Completion measure: Intervention Reach: Vaccination Next Step Initiation (Next HPV dose completion) measure: RCT Arm Effectiveness: Next HPV Vaccination Step Completion sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sea Mar Community Health Centers city: Seattle state: Washington zip: 98108 country: United States name: PREVENT Sea Mar CHC, Study Medical Coordinator, MsPH, MS role: CONTACT phone: 206-764-5504 email: LudyVillegas@seamarchc.org name: PREVENT Research Assistant role: CONTACT phone: 801-587-4565 email: Kepka-Research@hci.utah.edu name: Amanda Petrik, PhD role: PRINCIPAL_INVESTIGATOR lat: 47.60621 lon: -122.33207 hasResults: False
nctId: NCT06290180 id: 13632 id: 1S06GM146095 type: NIH link: https://reporter.nih.gov/quickSearch/1S06GM146095 briefTitle: Healing Lodge First Face Training Evaluation Study overallStatus: NOT_YET_RECRUITING date: 2024-04-04 date: 2025-03-31 date: 2025-03-31 date: 2024-03-04 date: 2024-03-04 name: Cambridge Health Alliance class: OTHER name: National Institute of General Medical Sciences (NIGMS) briefSummary: The purpose of this study is to evaluate a culturally grounded training program, xaʔtus (meaning First Face) for Mental Health. This program will train community members in how to recognize and respond to youth and adults experiencing mental health crises and ways to serve as a bridge between these individuals and the help they need. All Healing Lodge staff are being asked to complete First Face training.
To evaluate First Face, the investigators will ask all trainees to complete surveys before and after training, and again 3 months later. These surveys will measure knowledge about mental health and addiction, as well as the ability and confidence to respond appropriately to mental health crises. The study will help the investigators understand whether the First Face training program influences mental health and attitudes, as well as responses to mental health crisis situations. conditions: Addiction conditions: Depression/Anxiety conditions: Trauma, Psychological conditions: Self-harm studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Pre/post/3-month follow-up model primaryPurpose: PREVENTION masking: NONE count: 100 type: ESTIMATED name: First Face for Mental Heatlh measure: Attitudes Towards Serious Mental Illness - Adolescent Version measure: First Face knowledge assessment measure: Perceived Competence to Respond measure: Satisfaction with Training measure: Use of First Face learnings in professional/personal life measure: Intended Use of First Face learnings in professional/personal life sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Healing Lodge of the Seven Nations city: Spokane Valley state: Washington zip: 99212 country: United States name: Melinda Bowman, EdD role: CONTACT phone: 509-795-8342 email: melindab@healinglodge.org name: Michelle Zuckerman, EdD role: CONTACT phone: 509-533-6910 email: michellez@healinglodge.org name: Melinda Bowman, EdD role: PRINCIPAL_INVESTIGATOR lat: 47.67323 lon: -117.23937 typeAbbrev: SAP hasProtocol: False hasSap: True hasIcf: False label: Statistical Analysis Plan date: 2024-02-21 uploadDate: 2024-02-21T11:51 filename: SAP_000.pdf size: 52477 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2024-02-28 uploadDate: 2024-02-28T13:20 filename: ICF_001.pdf size: 251558 hasResults: False
nctId: NCT06290167 id: 30M201 briefTitle: A New 360° Dual-task Based Protocol for the Pre-clinical In-hospital and At-home Rehabilitation of Elderly: DUAL-Rehab acronym: DUAL-Rehab overallStatus: RECRUITING date: 2023-07-03 date: 2026-04-10 date: 2026-04-10 date: 2024-03-04 date: 2024-03-04 name: Istituto Auxologico Italiano class: OTHER briefSummary: The main objective of this project is two-fold
Expected outcome is an improvement in cognitive functioning (assessed with a complete neuropsychological battery) after the training, thus advancing literature about non-pharmacological interventions in the preclinical stages of dementia along with innovative technical instruments. conditions: Cognitive Decline studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: FACTORIAL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 90 type: ESTIMATED name: 360° media name: Treatment As Usual (TAU) name: In hospital sessions name: at home sessions name: Mild Cognitive Impairment name: Subjective Memory Complain measure: Cognitive functions measure: Motor functions sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: Istituto Auxologico Italiano IRCCS status: RECRUITING city: Milan state: MI zip: 20149 country: Italy name: Elisa Pedroli, PsyD role: CONTACT phone: 02 61911 2707 email: e.pedroli@auxologico.it lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06290154 id: RG2024-022-02 briefTitle: Factors Associated With Posttransplant Cardiac Outcomes overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-12-31 date: 2027-12-31 date: 2024-03-04 date: 2024-03-05 name: Sun Yat-sen University class: OTHER briefSummary: Cardiovascular disease has become the leading cause of death early after liver transplantation (LT). The aging LT population is accompanied with the increasing prevalence of cardiovascular risk factors such as hypertension, diabetes, and hyperlipidemia. Furthermore, cirrhosis has been known to cause alterations in the systemic haemodynamic system and cardiac muscle dysfunction, systolic and/or diastolic, known as Cirrhotic cardiomyopathy (CCM). Hence, transthoracic echocardiography is required in all LT candidates for preprocedural evaluation and risk stratification. However, traditional echocardiographic indices of cardiac function have low sensitivity. It is unclear whether comprehensive echocardiographic multiparameters, including speckle tracking echocardiograph (STE) and tissue doppler imaging (TDI) can help improve preoperative risk stratification. Therefore, we sought to analyze the ability of clinical and comprehensive echocardiography variables to predict intraoperative and perioperative cardiac events and cardiac mortality in our LT patient experience up to early post-liver transplant. conditions: Cardiovascular Diseases conditions: Liver Transplantation studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ESTIMATED measure: a composite outcome of new cardiovascular disease after liver transplantation sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06290115 id: 202301 briefTitle: Adolescents' Non-suicidal Behavior and Perception of Parents' Negative Emotional Expression and Family Communication overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-10-31 date: 2024-12-31 date: 2024-03-04 date: 2024-03-13 name: Sun Yat-sen University class: OTHER briefSummary: The starting point of this project is to study young people and adolescents, aiming to explore the correlation between non-suicidal behavior of young people and adolescents and the negative emotional expression of their parents and family communication. The purpose of this project is to investigate the non-suicidal self-injury behavior of teenagers aged 15-25 years by issuing questionnaires (sample size: 327 people). In order to find out whether there is any connection between family communication and non-suicidal self-injury behavior of young people and adolescents. conditions: Adolescents studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 324 type: ESTIMATED name: Questionnaires set 1 name: Questionnaires set 2 name: Questionnaires set 3 measure: Non-suicidal self-injury behavior of young people and adolescents measure: Expression of negative emotions of parents measure: Parent-Adolescent communication scale measure: Childhood Trauma Questionnaire measure: Parental Bongding Instrument measure: The parent-child relationship intimacy scale sex: ALL minimumAge: 15 Years maximumAge: 25 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06290102 id: TV56248-RES-10204 briefTitle: Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old overallStatus: RECRUITING date: 2024-05-02 date: 2024-10-02 date: 2024-11-09 date: 2024-03-04 date: 2024-04-24 name: Teva Branded Pharmaceutical Products R&D, Inc. class: INDUSTRY briefSummary: The primary objectives of this study are:
• To evaluate the safety of a single dose of TEV-56248 and a single dose of Fp MDPI conditions: Asthma studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE count: 22 type: ESTIMATED name: TEV-56248 name: Fp MDPI measure: Maximum Observed Plasma Drug Concentration (Cmax) of Fluticasone Propionate (Fp) measure: Maximum Observed Plasma Drug Concentration (Cmax) of Albuterol Sulfate(ABS) measure: Area Under the Plasma Drug Concentration-Time Curve from Time 0 to the Time of the Last Measurable Drug Concentration (AUC0-t) for Fp measure: Area Under the Plasma Drug Concentration-Time Curve from Time 0 to the Time of the Last Measurable Drug Concentration (AUC0-t) for ABS measure: Time to Maximum Observed Plasma Drug Concentration (tmax) for Fp measure: Time to Maximum Observed Plasma Drug Concentration (tmax) for ABS measure: Terminal Phase (Apparent Elimination) Half-Life (t½) of Fp measure: Terminal Phase (Apparent Elimination) Half-Life (t½) of ABS measure: Last Measurable Concentration Above the Quantification Limit (Clast) of Fp measure: Last Measurable Concentration Above the Quantification Limit (Clast) of ABS measure: Time of Last Measurable Concentration (tlast) of Fp measure: Time of Last Measurable Concentration (tlast) of ABS measure: Number of Participants with Adverse Events (AEs) measure: Number of Participants with Serious Adverse Events (SAEs) measure: Number of Participants Who Withdrawal From Trial Due to Treatment Emergent Adverse Events (TEAEs) sex: ALL minimumAge: 4 Years maximumAge: 11 Years stdAges: CHILD facility: Teva Investigational Site 12001 status: RECRUITING city: Boerne state: Texas zip: 78006 country: United States lat: 29.79466 lon: -98.73197 hasResults: False
nctId: NCT06290089 id: OEV-131 briefTitle: Pre-Study of Wild Type Enterotoxigenic E. Coli (ETEC) Strain for Verification of a Planned Challenge Dose overallStatus: RECRUITING date: 2024-02-12 date: 2024-06 date: 2024-09 date: 2024-03-04 date: 2024-04-12 name: Scandinavian Biopharma AB class: INDUSTRY name: Johns Hopkins Bloomberg School of Public Health briefSummary: This is an open label study with the aim to estimate the incidence of moderate and severe diarrhea among participants challenged with an enterotoxigenic E. coli (ETEC) strain. This strain is planned to be used in a subsequent challenge study on the efficacy of an oral inactivated ETEC vaccine.
The study will be conducted at one site; the Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland, United States. conditions: ETEC Diarrhea studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 30 type: ESTIMATED name: Enterotoxigenic E. coli (ETEC) strain measure: The incidence of moderate and severe diarrhea sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health status: RECRUITING city: Baltimore state: Maryland zip: 21205 country: United States name: Kawsar R. Talaat, MD role: CONTACT phone: 410-502-9627 email: ktalaat@jhu.edu name: Kawsar R. Talaat, MD role: PRINCIPAL_INVESTIGATOR lat: 39.29038 lon: -76.61219 hasResults: False
nctId: NCT06290076 id: IAT-PROACT briefTitle: A Predictive Model and Scoring System for Severe Complications After Endovascular Thrombectomy overallStatus: COMPLETED date: 2020-01-01 date: 2023-06-30 date: 2023-09-30 date: 2024-03-04 date: 2024-03-04 name: Xuanwu Hospital, Beijing class: OTHER briefSummary: To establish a predictive model and scoring system for predicting severe complications after thrombectomy. This scoring system can be used to identify high-risk patients after endovascular thrombectomy, guide the early use of adjunctive interventions, and provide reference for future clinical trials. conditions: Acute Ischemic Stroke conditions: Endovascular Thrombectomy conditions: Symptomatic Intracranial Hemorrhage conditions: Malignant Cerebral Edema studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 1500 type: ACTUAL measure: Rate of severe complications measure: Rate of mRS score of 3-6 measure: Rate of mRS score of 5-6 measure: Rate of symptomatic intracranial hemorrhage measure: Rate of malignant cerebral edema measure: Change of NIHSS score measure: Rate of modified Rankin Scale (mRS) score of 0-2 measure: All-cause mortality sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Xuanwu Hospital, Capital Medical University city: Beijing state: Beijing zip: 100053 country: China lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06290063 id: 22-08-0138 briefTitle: Cannabidiol and Older Adult Cannabis Users acronym: QUARTz overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2028-08-31 date: 2028-08-31 date: 2024-03-04 date: 2024-03-04 name: University of Colorado, Boulder class: OTHER briefSummary: Cannabis use increased 10 fold among adults over the age of 65 between 2014 and 2016 but very little data exists on the extent of their harmful effects on health and behavior. The overarching goal of this project is to test a novel harm reduction strategy in which older individuals who seek to use cannabis for pain, anxiety or mood problems (depression/anxiety) will be randomly assigned to one of three conditions in an 8 week randomized controlled trial: hemp-derived CBD+THC, hemp-derived CBD-THC, or placebo. This work has the ability to directly inform individual choices regarding the use of cannabis products among older adults, and direct policy decisions regulating cannabis formulations on the legal market. conditions: Sleep conditions: Anxiety conditions: Depression conditions: Pain studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 385 type: ESTIMATED name: fsCBD Cannabidiol name: bsCBD Cannabidiol name: Placebo measure: Subjective Motor Function measure: Balance measure: Anxiety measure: Depression measure: Blood Cytokine Levels measure: Depression/Anxiety measure: Drug Effects measure: Inhibitory Control measure: Cognitive Function measure: Pain Intensity and Interference measure: Cognitive Ability measure: Pain Intensity measure: Change in Condition measure: Sleep Disturbance measure: Sleep-Related Impairment measure: Memory measure: Polypharmacy-Pain Medications measure: Polypharmacy-Psychiatric Medications measure: Polypharmacy-Sleep Medications measure: Strength and Endurance measure: Sleep Quality sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Colorado at Boulder city: Boulder state: Colorado zip: 80309 country: United States name: Ellie Sundali, BA role: CONTACT email: ellie.sundali@colorado.edu lat: 40.01499 lon: -105.27055 hasResults: False
nctId: NCT06290050 id: TAK-279-1006 briefTitle: A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults overallStatus: RECRUITING date: 2024-03-29 date: 2024-05-03 date: 2024-05-16 date: 2024-03-04 date: 2024-04-24 name: Takeda class: INDUSTRY briefSummary: The main aim of this study is to find out how several doses of TAK-279 affects the body of healthy adults and processes midazolam and repaglinide (pharmacokinetics or PK). Another aim is to learn about the side effects of TAK-279 and how well it is tolerated when given to healthy adults either alone or together with midazolam or repaglinide.
During the study, participants will need to stay at the clinic for 19 days. Blood samples will be taken at several timepoints during the study. The study drug will be given by mouth (orally). conditions: Healthy Volunteers studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: OTHER masking: NONE count: 20 type: ESTIMATED name: Midazolam name: Repaglinide name: TAK-279 measure: Cmax: Maximum Observed Plasma Concentration for Midazolam and Repaglinide When Administered Alone and With TAK-279 measure: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Midazolam and Repaglinide When Administered Alone and With TAK-279 measure: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Midazolam and Repaglinide When Administered Alone and With TAK-279 measure: Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESI) sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Celerion status: RECRUITING city: Tempe state: Arizona zip: 85283 country: United States name: Study Contact role: CONTACT phone: 480-415-7404 email: mara.baier@celerion.com name: Mara Baier, DO role: PRINCIPAL_INVESTIGATOR lat: 33.41477 lon: -111.90931 hasResults: False
nctId: NCT06290037 id: 2024-01-003 briefTitle: Driving Ability Evaluation System to Improve the Conditional Driving License System: Feasibility Study of High-risk Drivers. overallStatus: RECRUITING date: 2024-03-15 date: 2024-12-31 date: 2024-12-31 date: 2024-03-04 date: 2024-03-04 name: Seoul National University Hospital class: OTHER briefSummary: The primary objective of this study is to verify the safety and validity of a VR driving simulator developed for evaluating the driving abilities of elderly drivers.
This study also aims to establish indicators in VR driving simulator to evaluate high-risk group for driving, such as cognitive and physical abilities. Therefore, this study aims to measure the physical driving function, general physical function and cognitive function of elderly drivers. to identify the correlation between their outcomes and the VR driving simulator's result conditions: Automobile Driving studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SCREENING masking: NONE count: 100 type: ESTIMATED name: VR Driving Simulator name: Computerized Neurocognitive Function Test name: Driver Test Station name: Short Physical Performance Battery name: On-road field driving Test measure: Feasibility of VR driving simulator measure: Driving performance in simulator, measured by driving errors sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: Seoul National University Hospital status: RECRUITING city: Seoul country: Korea, Republic of name: Ja-Ho Leigh, M.D. Msc. role: CONTACT email: mazican@gmail.com lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06290024 id: XH-23-013 briefTitle: A Multi-center Clinical Longitudinal Study of Neuropathic Pain by Collecting Data overallStatus: RECRUITING date: 2023-08-15 date: 2024-08-15 date: 2024-08-15 date: 2024-03-04 date: 2024-04-02 name: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine class: OTHER briefSummary: A multi-center clinical longitudinal study of neuropathic pain by collecting data on patients' brain physiology and cognitive function conditions: Pain studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: OTHER count: 2000 type: ESTIMATED name: A multi-center clinical longitudinal study of neuropathic pain by collecting data on patients' brain physiology and cognitive function measure: Visual Analogue Scale/Score（VAS） measure: digital pain grading method (NRS) measure: neuropathic pain assessment scale (DN4) measure: sleep quality (Pittsburgh sleep quality index, Ascens insomnia scale) measure: EEG measure: Barrett impulse scale (BIS) measure: (Generalized Anxiety Disorder,GAD-7) measure: (Patient Health Questionnaire-9 measure: Montreal cognitive assessment scale (MoCA) measure: ocial support assessment scale (SSQ) sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ke Ma status: RECRUITING city: Shanghai state: Yangpu zip: 200092 country: China name: Ke NA Ma, PHD role: CONTACT phone: 13361879260 email: marke72@163.com lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06290011 id: XH-23-014 briefTitle: A Clinical Study on the Efficacy of Cognitive Distraction Focus Relaxation Therapy Based on MR overallStatus: RECRUITING date: 2023-10-11 date: 2024-10-11 date: 2024-10-11 date: 2024-03-04 date: 2024-03-04 name: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine class: OTHER briefSummary: A prospective, single blind, randomized, parallel controlled trial was conducted to evaluate the analgesic effect and safety of MR based "cognitive distraction focus relaxation therapy" in patients clinically diagnosed with chronic moderate to severe pain conditions: Pain studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: OTHER count: 132 type: ESTIMATED name: Pain key group measure: Visual Analogue Scale/Score（VAS） sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ke Ma status: RECRUITING city: Shanghai state: Yangpu zip: 200092 country: China name: Ke NA Ma, PHD role: CONTACT phone: 13361879260 email: marke72@163.com lat: 31.22222 lon: 121.45806 hasResults: False